Aulos Bioscience

About:

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

Website: https://www.aulosbio.com/

Top Investors: Apple Tree Partners

Description:

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Their initial clinical candidate, AU-007, stands apart from existing IL-2 therapeutics by introducing a novel approach that addresses a significant medical challenge of the present era: the eradication of cancer. Through harnessing the anti-cancer potential of interleukin-2, they are breaking down barriers in the field of immuno-oncology. Their distinctive immunotherapy, computationally designed to precisely guide the immune system in attacking tumor cells, is poised to make a substantial impact.

Total Funding Amount:

$60M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2020-01-01

Founders:

Micah Pearlman, Michael Ehlers, Yanay Ofran

Number of Employees:

11-50

Last Funding Date:

2023-08-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai